Novel pharmacological targets for the treatment of Parkinson's disease

A H V Schapira; E Bezard; J Brotchie; F Calon; G L Collingridge; B Ferger; B Hengerer; E Hirsch; P Jenner; N Le Novere; J A Obeso; M A Schwarzschild; U Spampinato; G Davidai

doi:10.1038/nrd2087

Novel pharmacological targets for the treatment of Parkinson's disease

A H V Schapira, E Bezard, J Brotchie, F Calon, G L Collingridge, B Ferger, B Hengerer, E Hirsch, P Jenner, N Le Novere, J A Obeso, M A Schwarzschild, U Spampinato, G Davidai

King's College London

Research output: Contribution to journal › Literature review › peer-review

282 Citations (Scopus)

Abstract

Dopamine deficiency, caused by the degeneration of nigrostriatal dopaminergic neurons, is the cause of the major clinical motor symptoms of Parkinson's disease. These symptoms can be treated successfully with a range of drugs that include levodopa, inhibitors of the enzymatic breakdown of levodopa and dopamine agonists delivered by oral, subcutaneous, transcutaneous, intravenous or intra-duodenal routes. However, Parkinson's disease involves degeneration of non-dopaminergic neurons and the treatment of the resulting predominantly non-motor features remains a challenge. This review describes the important recent advances that underlie the development of novel dopaminergic and non-dopaminergic drugs for Parkinson's disease, and also for the motor complications that arise from the use of existing therapies

Original language	English
Pages (from-to)	845 - 854
Number of pages	10
Journal	Nature Reviews Drug Discovery
Volume	5
Issue number	10
DOIs	https://doi.org/10.1038/nrd2087
Publication status	Published - Oct 2006

Access to Document

10.1038/nrd2087

Cite this

@article{05b1e0e77f8e49a0bda8b5a2e56a3489,

title = "Novel pharmacological targets for the treatment of Parkinson's disease",

abstract = "Dopamine deficiency, caused by the degeneration of nigrostriatal dopaminergic neurons, is the cause of the major clinical motor symptoms of Parkinson's disease. These symptoms can be treated successfully with a range of drugs that include levodopa, inhibitors of the enzymatic breakdown of levodopa and dopamine agonists delivered by oral, subcutaneous, transcutaneous, intravenous or intra-duodenal routes. However, Parkinson's disease involves degeneration of non-dopaminergic neurons and the treatment of the resulting predominantly non-motor features remains a challenge. This review describes the important recent advances that underlie the development of novel dopaminergic and non-dopaminergic drugs for Parkinson's disease, and also for the motor complications that arise from the use of existing therapies",

author = "Schapira, {A H V} and E Bezard and J Brotchie and F Calon and Collingridge, {G L} and B Ferger and B Hengerer and E Hirsch and P Jenner and {Le Novere}, N and Obeso, {J A} and Schwarzschild, {M A} and U Spampinato and G Davidai",

year = "2006",

month = oct,

doi = "10.1038/nrd2087",

language = "English",

volume = "5",

pages = "845 -- 854",

journal = "Nature Reviews Drug Discovery",

publisher = "Nature Publishing Group",

number = "10",

}

TY - JOUR

T1 - Novel pharmacological targets for the treatment of Parkinson's disease

AU - Schapira, A H V

AU - Bezard, E

AU - Brotchie, J

AU - Calon, F

AU - Collingridge, G L

AU - Ferger, B

AU - Hengerer, B

AU - Hirsch, E

AU - Jenner, P

AU - Le Novere, N

AU - Obeso, J A

AU - Schwarzschild, M A

AU - Spampinato, U

AU - Davidai, G

PY - 2006/10

Y1 - 2006/10

N2 - Dopamine deficiency, caused by the degeneration of nigrostriatal dopaminergic neurons, is the cause of the major clinical motor symptoms of Parkinson's disease. These symptoms can be treated successfully with a range of drugs that include levodopa, inhibitors of the enzymatic breakdown of levodopa and dopamine agonists delivered by oral, subcutaneous, transcutaneous, intravenous or intra-duodenal routes. However, Parkinson's disease involves degeneration of non-dopaminergic neurons and the treatment of the resulting predominantly non-motor features remains a challenge. This review describes the important recent advances that underlie the development of novel dopaminergic and non-dopaminergic drugs for Parkinson's disease, and also for the motor complications that arise from the use of existing therapies

AB - Dopamine deficiency, caused by the degeneration of nigrostriatal dopaminergic neurons, is the cause of the major clinical motor symptoms of Parkinson's disease. These symptoms can be treated successfully with a range of drugs that include levodopa, inhibitors of the enzymatic breakdown of levodopa and dopamine agonists delivered by oral, subcutaneous, transcutaneous, intravenous or intra-duodenal routes. However, Parkinson's disease involves degeneration of non-dopaminergic neurons and the treatment of the resulting predominantly non-motor features remains a challenge. This review describes the important recent advances that underlie the development of novel dopaminergic and non-dopaminergic drugs for Parkinson's disease, and also for the motor complications that arise from the use of existing therapies

U2 - 10.1038/nrd2087

DO - 10.1038/nrd2087

M3 - Literature review

VL - 5

SP - 845

EP - 854

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

IS - 10

ER -

Novel pharmacological targets for the treatment of Parkinson's disease

Abstract

Access to Document

Fingerprint

Cite this